ArticleNeurology and therapy2026
Smartphone-Based Multimodal Digital Biomarker Integration for Parkinson's Disease Screening and Diagnostic Support.
Article in Neurology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
introductionTimely identification of Parkinson's disease (PD) is often delayed because of clinical heterogeneity and limited awareness of early symptoms. Digital biomarkers obtained via smartphones offer scalable screening potential. However, unimodal assessments may lack sufficient sensitivity or specificity given the multidimensional nature of PD. The aim of this study was to develop and validate a smartphone-based, multimodal digital biomarker framework for PD screening and diagnostic support.
methodsThe study progressed through two phases: an initial version [n = 368; 233 PD, 135 healthy controls (HC)] was used for data-driven task refinement, and a final version (n = 296; 204 PD, 92 HC) containing optimized motor (Touch, Swipe, Balloon, Spiral, Wave), visual, and speech tasks and a refined questionnaire task was evaluated. Feature selection and speech subtask selection were performed exclusively within the training set using stratified cross-validation. Random Forest and XGBoost classifiers were trained using (1) single-task features, (2) all-task multimodal features, and (3) selected task subsets. The primary outcome was area under the receiver operating characteristic curve (AUROC) on the independent test set.
resultsIn the final version, single-task models demonstrated heterogeneous performance (Random Forest AUROC range 0.5689-0.8397), with the questionnaire (0.8397) and Touch task (0.7789) performing best individually. The all-task multimodal model achieved AUROC 0.8620. A reduced multimodal subset combining Touch, Spiral, and questionnaire features yielded the highest discriminative performance (AUROC 0.9053). Additional feature- and task-level analyses showed significant multivariate group differences (Hotelling's T
conclusionA smartphone-only multimodal digital biomarker framework achieved high discrimination between PD and controls. Multimodal integration outperformed unimodal approaches, supporting the potential utility of scalable, smartphone-based tools for PD screening and diagnostic support. External validation in broader populations is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.